Celcuity Appoints Oncology Commercialization Expert Charles Romp to Board

summarizeSummary

Celcuity Inc. appointed Charles Romp, an experienced oncology commercialization executive, to its Board of Directors, signaling a strategic focus on preparing for the potential launch of its lead drug candidate.

check_boxKey Events

• New Director Appointed

  Charles (Chip) R. Romp was appointed to the Board of Directors, effective February 11, 2026, increasing the board size from seven to eight members.

• Strategic Oncology Expertise

  Mr. Romp brings over 25 years of experience in the pharmaceutical industry, with a strong focus on leading sales and commercial organizations in oncology, including roles at Seagen and Genentech.

• Support for Gedatolisib Commercialization

  The appointment is highlighted by the CEO as providing 'valuable insight' as the company advances its programs and prepares for the potential approval and launch of gedatolisib, its lead oncology therapeutic candidate.

• Standard Director Compensation

  Mr. Romp will receive an annual cash retainer of $50,000 and an annual equity award with a fair market value of $100,000, along with a pro-rated grant of 215 restricted shares upon appointment.

auto_awesomeAnalysis

Celcuity Inc. has strategically strengthened its Board of Directors with the appointment of Charles Romp, an industry veteran with over 25 years of experience in oncology commercialization. This move is particularly significant for a clinical-stage biotechnology company like Celcuity, as it prepares for the potential approval and launch of its lead therapeutic candidate, gedatolisib, later this year. Romp's expertise from companies like Seagen and Genentech will be invaluable in guiding the company's commercial strategy and market penetration in the highly competitive oncology space.